2,03 €
2,07 %vorgestern
L&S, 1. März, 22:55 Uhr
ISIN
US2210151005
Symbol
CRVS
Berichte
Sektor
Industrie

Corvus Pharmaceuticals, Inc. Aktie News

Neutral
GlobeNewsWire
20 Tage alt
Poster presentation unveils Corvus' next-generation ITK inhibitor candidates designed to deliver precise T cell modulation for immunology indications Poster presentation unveils Corvus' next-generation ITK inhibitor candidates designed to deliver precise T cell modulation for immunology indications
Neutral
GlobeNewsWire
etwa ein Monat alt
BURLINGAME, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to announce the passing of Edith P. Mitchell, M.D., a valued member of the Board of Directors. The Company extends its condolences to her family, colleagues and community.
Positiv
Seeking Alpha
3 Monate alt
Corvus Pharmaceuticals is a clinical-stage company with potential investment opportunities and a focus on the ITK inhibitor soquelitinib. The company is targeting relapsed peripheral T-cell lymphoma with plans to begin a Phase 3 clinical trial early next year. PTCL is a subtype of lymphoma that currently has limited treatment options, making it a high-potential market for Corvus Pharmaceuticals.
Neutral
GlobeNewsWire
3 Monate alt
Anti-tumor activity and durability of responses data support advancement of soquelitinib (formerly known as CPI-818) into Phase 3 registrational clinical trial and its potential to address the need for new treatments for peripheral T cell lymphoma (PTCL)
Neutral
Seeking Alpha
4 Monate alt
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Zack Kubow - Real Chemistry Leiv Lea - CFO Richard Miller - CEO Jim Rosenbaum - SVP of Research Conference Call Participants Aydin Huseynov - Ladenberg Jeff Jones - Oppenheimer Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the C...
Neutral
GlobeNewsWire
4 Monate alt
Protocol finalized for soquelitinib (CPI-818) Phase 3 registrational clinical trial in peripheral T cell lymphoma (PTCL); multiple sites preparing to initiate trial enrollment
Neutral
GlobeNewsWire
4 Monate alt
BURLINGAME, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new interim data from its Phase 1/1b trial of soquelitinib in patients with relapsed peripheral T cell lymphoma (PTCL), at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking pla...
Neutral
GlobeNewsWire
4 Monate alt
Data demonstrated soquelitinib was active in six inflammatory/immune disease models and provides rationale for development in a range of additional Th2- and Th17-mediated diseases

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen